Monday, December 01, 2008
The book is available at the LexisNexis Online Bookstore. My publishers will ship the book to any where in India for just Re 1. Keeping the touch with the difficult times that lie ahead of us, the book is priced at Rs.295 /-
Title: The Touchstone Effect: The Impact of Pre-grant Opposition on Patents
Author: Feroz Ali Khader
Publisher: LexisNexis Butterworths Wadhwa Nagpur
Format: Soft Cover
Price: INR 295.00 / US$ 14.75
Pages: xx + 166 pages (Appendices starts from pg 137, followed by Chapter Notes and Subject Index).
Wednesday, April 09, 2008
Justice AR Lakshmanan, Chairman Law Commission of India; Justice PP
Naolekar, Judge Supreme Court of India; Justice Ravindra Bhat, Judge Delhi
High Court; Justice DV Shylendra Kumar, Judge Karnataka High Court
Dr. Anil Gupta, IIM Ahmedabad; Shamnad Basheer, Oxford IP Research Centre;
Srividhya Raghavan, Oklahoma University; T. Ramakrishna, NLSIU; Sudhir
Aditya Sondhi, Advocate Karnataka High Court; Vinay Aravind, Poovayya & Poovayya
Leena Menghaney, Access Campaign Manager - India, MSF; Mr. Gopa Kumar,
CENTAD; Dr. Anand Grover, Director, Lawyers' Collective
Friday, April 04, 2008
Wednesday, April 02, 2008
Tuesday, April 01, 2008
Friday, March 28, 2008
Thursday, February 28, 2008
Tuesday, February 26, 2008
4.5.3 The examiner makes comparison with regard to properties or enhancement of efficacy between the known substance and the new form of known substance. In case the new form is further converted into another new form, the comparison is made between the already existing form and another new form but not between the base compound and another new form.
4.5.4 The comparison with regard to properties or enhancement of efficacy is required to be made at the time of date of filing of the application or priority date if the application is claiming the priority of any earlier application but not at the stage of subsequent development.
4.5.5 The efficacy need not be quantified in terms of numerical value to determine whether the product is efficacious because it is not possible to have a standard numerical value for efficacy for all products including pharmaceutical products.
Like any effort, there is scope for improvement and the good thing is that the Patent Office believes so. Please send your comments to the Patent Office on any suggestion and improvements by 25 March 2008. It is a good effort and your participation will certainly make things better.